Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium
https://pubmed.ncbi.nlm.nih.gov/36600534/Actively Recruiting
Led by Leiden University Medical Center · Updated on 2026-10-08
316
Participants Needed
60
Research Sites
52 weeks
Total Duration
The trial investigates adjuvant treatment options for women with endometrial cancer characterized by mismatch repair deficiency MMRd. It is a phase III international, multicenter, randomized study comparing pelvic external beam radiotherapy combined with and followed by durvalumab for one year to pelvic external beam radiotherapy with or without chemotherapy. This trial is part of the larger RAINBO research project which aims to refine adjuvant treatment based on molecular features of endometrial cancer. Participants receive either pelvic external beam radiotherapy alone or combined with chemotherapy according to the PORTEC-3 schedule, or pelvic external beam radiotherapy plus durvalumab given intravenously every 4 weeks for 13 cycles one year. Vaginal brachytherapy may be considered for certain patients with specific tumor involvement. The trial includes detailed radiation dosing and chemotherapy regimens, with durvalumab starting within the first week of radiotherapy. Participants will be monitored for recurrence-free survival over three years, along with efficacy, quality of life, safety, and biomarker outcomes for up to five years. Assessments include clinical evaluations, imaging, laboratory tests, and translational research on tumor material. The study requires follow-up and treatment accessibility, with informed consent and permissions for research use of tissue and data. The total duration includes treatment and long-term follow-up to evaluate treatment impact and safety.
CONDITIONS
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
E
Elma Meershoek- Klein Kranenbarg
A
Annet Roodvoets
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Leiden University Medical Center
Lead Sponsor
Dutch Gynaecological Oncology Group
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 1 year
Participants receive pelvic external beam radiotherapy combined with or without chemotherapy, and those in the experimental group also receive durvalumab intravenously every 4 weeks for one year.
Regular visits during radiotherapy and durvalumab cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
RAINBO Research Consortium
https://pubmed.ncbi.nlm.nih.gov/36600534/Angeles Alvarez Secord, Matthew A Powell, Jessica McAlpine
https://pubmed.ncbi.nlm.nih.gov/40966692/Leiden University Medical Center
Lead Sponsor
Dutch Gynaecological Oncology Group
Collaborating Sponsor